person · Reporting owner

Albers Jeffrey W.

Disclosed activity across 4 companies

Tapewire entity: 24935
SEC CIK: 0001638474

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813	Director	June 28, 2022	June 30, 2022
Kymera Therapeutics, Inc.KYMR · Entity 3545	Director	June 24, 2026	June 25, 2026
Spyre Therapeutics, Inc.SYRE · Entity 2649	Director	August 07, 2026	August 11, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Dianthus Therapeutics, Inc. /DE/

Report date June 28, 2022 · Filed June 30, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2032-06-27	Direct	20,000	Reported balance After 2022-06-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-28 · Grant · Acquired 20,000 · Balance 20,000 F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders.

Kymera Therapeutics, Inc.

Report date June 24, 2026 · Filed June 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.87 · Expires 2036-06-23	Direct	6,068	Reported balance After 2026-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-24 · Grant · Acquired 6,068 · Balance 6,068 F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

Spyre Therapeutics, Inc.

Report date August 07, 2026 · Filed August 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2026-08-07 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-07 · Exercise / conversion · Acquired 5,000 · Balance 5,000 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. Row 2 · 2026-08-07 · Sale · Disposed 5,000 · Balance 0 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
Common StockSEC Table I · non-derivative	IndirectBy Sessions LLC	19,360	Reported balance After 2026-08-07 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-08-07 · Sale · Disposed 8,000 · Balance 19,360 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Common StockSEC Table I · non-derivative	IndirectBy Sessions LLC	9,360	Reported balance After 2026-08-07 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2026-08-07 · Sale · Disposed 10,000 · Balance 9,360 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.39 · Expires 2033-11-22	Direct	45,000	Reported balance After 2026-08-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-08-07 · Exercise / conversion · Disposed 5,000 · Balance 45,000 F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. F5: This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.

F2: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Blueprint Medicines Corp

Report date July 17, 2025 · Filed July 21, 2025

Section 16 reporting ended · disclosed 2025-07-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2025-07-17 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-07-17 · Disposition to issuer · Disposed 5,777 · Balance 144,755 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration. Row 2 · 2025-07-17 · Other · Disposed 144,755 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.05	Direct	Reported balance After 2025-07-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-07-17 · Disposition to issuer · Disposed 92,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.44	Direct	Reported balance After 2025-07-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-07-17 · Disposition to issuer · Disposed 170,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.60	Direct	Reported balance After 2025-07-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-07-17 · Disposition to issuer · Disposed 110,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.13	Direct	Reported balance After 2025-07-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-07-17 · Disposition to issuer · Disposed 90,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.13	Direct	Reported balance After 2025-07-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-07-17 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31	Direct	Reported balance After 2025-07-17 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-07-17 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.66	Direct	Reported balance After 2025-07-17 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-07-17 · Disposition to issuer · Disposed 5,300 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.14	Direct	Reported balance After 2025-07-17 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-07-17 · Disposition to issuer · Disposed 4,570 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 05, 2018 Filed Nov 7, 2018 16:25 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $1.87	$0.00	Disclosure SEC source: 0001179110-18-012637 · edgar.xml · derivative · entry 6 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 915,034 Underlying: Common Stock · 20,000 shares Expires 2024-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F7 · derivative.exercise_date: This option was granted on July 30, 2014. This option vests as follows: (i) 42,845 shares vested in four installments at a rate of 6,974 shares on September 21, 2016, and 11,957 shares on each of October 21, 2016 and November 21, 2016, and 11,957 on December 21, 2016; (ii) 90,010 shares vested in eight installments at a rate of 6,311 shares on May 21, 2017 and 11,957 shares on each of June 21, 2017, July 21, 2017, August 21, 2017, September 21, 2017, October 21, 2017, November 21, 2017 and December 21, 2017; and (iii) 30,225 shares vest in three installments at a rate of 6,311 shares on May 21, 2018, 11,957 shares on June 21, 2018 and 11,957 shares on July 21, 2018. Read SEC document
November 05, 2018 Filed Nov 7, 2018 16:25 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	100	$62.66	$6,266.00	Disclosure SEC source: 0001179110-18-012637 · edgar.xml · nonDerivative · entry 5 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.65 to $62.66 per share. Read SEC document
November 05, 2018 Filed Nov 7, 2018 16:25 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	17,300	$63.30	$1,095,090.00	Disclosure SEC source: 0001179110-18-012637 · edgar.xml · nonDerivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.77 to $63.76 per share. Read SEC document
November 05, 2018 Filed Nov 7, 2018 16:25 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,500	$64.18	$96,270.00	Disclosure SEC source: 0001179110-18-012637 · edgar.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,400 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.84 to $64.81 per share. Read SEC document
November 05, 2018 Filed Nov 7, 2018 16:25 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,100	$65.53	$72,083.00	Disclosure SEC source: 0001179110-18-012637 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,900 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.04 to $66.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form 4. Read SEC document
November 05, 2018 Filed Nov 7, 2018 16:25 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	20,000	$1.87	$37,400.00	Disclosure SEC source: 0001179110-18-012637 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document
August 06, 2018 Filed Aug 8, 2018 16:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $1.87	$0.00	Disclosure SEC source: 0001179110-18-010389 · edgar.xml · derivative · entry 6 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,034 Underlying: Common Stock · 20,000 shares Expires 2024-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F7 · derivative.exercise_date: This option was granted on July 30, 2014. This option vests as follows: (i) 42,845 shares vested in four installments at a rate of 6,974 shares on September 21, 2016, and 11,957 shares on each of October 21, 2016 and November 21, 2016, and 11,957 on December 21, 2016; (ii) 90,010 shares vested in eight installments at a rate of 6,311 shares on May 21, 2017 and 11,957 shares on each of June 21, 2017, July 21, 2017, August 21, 2017, September 21, 2017, October 21, 2017, November 21, 2017 and December 21, 2017; and (iii) 30,225 shares vest in three installments at a rate of 6,311 shares on May 21, 2018, 11,957 shares on June 21, 2018 and 11,957 shares on July 21, 2018. Read SEC document
August 06, 2018 Filed Aug 8, 2018 16:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	802	$68.48	$54,920.96	Disclosure SEC source: 0001179110-18-010389 · edgar.xml · nonDerivative · entry 5 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.36 to $68.69 per share. Read SEC document
August 06, 2018 Filed Aug 8, 2018 16:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	800	$69.64	$55,712.00	Disclosure SEC source: 0001179110-18-010389 · edgar.xml · nonDerivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 802 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.55 to $69.79 per share. Read SEC document
August 06, 2018 Filed Aug 8, 2018 16:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	12,219	$70.48	$861,195.12	Disclosure SEC source: 0001179110-18-010389 · edgar.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,602 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.84 to $70.82 per share. Read SEC document
August 06, 2018 Filed Aug 8, 2018 16:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	6,179	$71.22	$440,068.38	Disclosure SEC source: 0001179110-18-010389 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,821 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.84 to $71.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form 4. Read SEC document
August 06, 2018 Filed Aug 8, 2018 16:08 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	20,000	$1.87	$37,400.00	Disclosure SEC source: 0001179110-18-010389 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:27 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	ConversionSeries C Preferred Stock · Derivative	10,729	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-018323 · doc4.xml · derivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,152 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. F1 · price: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:27 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	ConversionCommon Stock	4,152	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-018323 · doc4.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Series C Preferred Stock had no expiration date. Read SEC document
May 07, 2018 Filed May 9, 2018 16:29 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $1.87	$0.00	Disclosure SEC source: 0001179110-18-006475 · edgar.xml · derivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955,034 Underlying: Common Stock · 20,000 shares Expires 2024-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 30, 2014. This option vests as follows: (i) 42,845 shares vested in four installments at a rate of 6,974 shares on September 21, 2016, and 11,957 shares on each of October 21, 2016 and November 21, 2016, and 11,957 on December 21, 2016; (ii) 90,010 shares vested in eight installments at a rate of 6,311 shares on May 21, 2017 and 11,957 shares on each of June 21, 2017, July 21, 2017, August 21, 2017, September 21, 2017, October 21, 2017, November 21, 2017 and December 21, 2017; and (iii) 30,225 shares vest in three installments at a rate of 6,311 shares on May 21, 2018, 11,957 shares on June 21, 2018 and 11,957 shares on July 21, 2018. Read SEC document
May 07, 2018 Filed May 9, 2018 16:29 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	8,320	$78.56	$653,619.20	Disclosure SEC source: 0001179110-18-006475 · edgar.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.06 to $78.83 per share. Read SEC document
May 07, 2018 Filed May 9, 2018 16:29 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	11,680	$79.15	$924,472.00	Disclosure SEC source: 0001179110-18-006475 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,320 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Exchange Act. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.84 to $79.83 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. Read SEC document
May 07, 2018 Filed May 9, 2018 16:29 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	20,000	$1.87	$37,400.00	Disclosure SEC source: 0001179110-18-006475 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document
March 02, 2018 Filed Mar 6, 2018 16:55 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $1.87	$0.00	Disclosure SEC source: 0001179110-18-003644 · edgar.xml · derivative · entry 9 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 975,034 Underlying: Common Stock · 20,000 shares Expires 2024-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: This option was granted on July 30, 2014. This option vests as follows: (i) 42,845 shares vested in four installments at a rate of 6,974 shares on September 21, 2016, and 11,957 shares on each of October 21, 2016 and November 21, 2016, and 11,957 on December 21, 2016; (ii) 90,010 shares vested in eight installments at a rate of 6,311 shares on May 21, 2017 and 11,957 shares on each of June 21, 2017, July 21, 2017, August 21, 2017, September 21, 2017, October 21, 2017, November 21, 2017 and December 21, 2017; and (iii) 30,225 shares vest in three installments at a rate of 6,311 shares on May 21, 2018, 11,957 shares on June 21, 2018 and 11,957 shares on July 21, 2018. Read SEC document
March 02, 2018 Filed Mar 6, 2018 16:55 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,300	$88.17	$114,621.00	Disclosure SEC source: 0001179110-18-003644 · edgar.xml · nonDerivative · entry 8 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016, as amended December 20, 2017, pursuant to Rule 10b5-1 under the Exchange Act. F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.79 to $88.48 per share. Read SEC document
March 02, 2018 Filed Mar 6, 2018 16:55 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	2,284	$89.07	$203,435.88	Disclosure SEC source: 0001179110-18-003644 · edgar.xml · nonDerivative · entry 7 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016, as amended December 20, 2017, pursuant to Rule 10b5-1 under the Exchange Act. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.63 to $89.50 per share. Read SEC document
March 02, 2018 Filed Mar 6, 2018 16:55 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	600	$90.52	$54,312.00	Disclosure SEC source: 0001179110-18-003644 · edgar.xml · nonDerivative · entry 6 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,584 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016, as amended December 20, 2017, pursuant to Rule 10b5-1 under the Exchange Act. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.33 to $90.74 per share. Read SEC document
March 02, 2018 Filed Mar 6, 2018 16:55 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	4,100	$91.66	$375,806.00	Disclosure SEC source: 0001179110-18-003644 · edgar.xml · nonDerivative · entry 5 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,184 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016, as amended December 20, 2017, pursuant to Rule 10b5-1 under the Exchange Act. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.32 to $92.24 per share. Read SEC document
March 02, 2018 Filed Mar 6, 2018 16:55 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,900	$92.76	$176,244.00	Disclosure SEC source: 0001179110-18-003644 · edgar.xml · nonDerivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,284 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016, as amended December 20, 2017, pursuant to Rule 10b5-1 under the Exchange Act. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.44 to $93.25 per share. Read SEC document
March 02, 2018 Filed Mar 6, 2018 16:55 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	3,794	$93.89	$356,218.66	Disclosure SEC source: 0001179110-18-003644 · edgar.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,184 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016, as amended December 20, 2017, pursuant to Rule 10b5-1 under the Exchange Act. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.37 to $94.30 per share. Read SEC document
March 02, 2018 Filed Mar 6, 2018 16:55 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	6,022	$94.79	$570,825.38	Disclosure SEC source: 0001179110-18-003644 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,978 F2 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016, as amended December 20, 2017, pursuant to Rule 10b5-1 under the Exchange Act. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.31 to $95.30 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (9) to this Form 4. Read SEC document
March 02, 2018 Filed Mar 6, 2018 16:55 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	20,000	$1.87	$37,400.00	Disclosure SEC source: 0001179110-18-003644 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 17, 2016, as amended December 20, 2017, pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Read SEC document
February 16, 2018 Filed Feb 20, 2018 17:29 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	170,000	$0.00 Strike: $81.44	$0.00	Disclosure SEC source: 0001179110-18-002406 · edgar.xml · derivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 995,034 Underlying: Common Stock · 170,000 shares Expires 2028-02-16 F1 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on March 16, 2018 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document
November 06, 2017 Filed Nov 8, 2017 16:21 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	24,514	$0.00 Strike: $1.87	$0.00	Disclosure SEC source: 0001179110-17-013874 · edgar.xml · derivative · entry 8 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 825,034 Underlying: Common Stock · 24,514 shares Expires 2024-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This option was granted on July 30, 2014. This option vested as follows: (i) 12,620 shares vested in two installments at a rate of 6,310 shares on December 21, 2015 and May 21, 2016; (ii) 35,871 shares vested in three installments at a rate of 11,957 on June 21, 2016, July 21, 2016 and August 21, 2016; and (iii) 4,983 shares vested on September 21, 2016. Read SEC document
November 06, 2017 Filed Nov 8, 2017 16:21 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,100	$68.95	$75,845.00	Disclosure SEC source: 0001179110-17-013874 · edgar.xml · nonDerivative · entry 7 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.65 to $69.10 per share. Read SEC document
November 06, 2017 Filed Nov 8, 2017 16:21 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	16,469	$69.74	$1,148,548.06	Disclosure SEC source: 0001179110-17-013874 · edgar.xml · nonDerivative · entry 6 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.13 to $70.12 per share. Read SEC document
November 06, 2017 Filed Nov 8, 2017 16:21 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	7,432	$70.40	$523,212.80	Disclosure SEC source: 0001179110-17-013874 · edgar.xml · nonDerivative · entry 5 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,569 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.13 to $71.12 per share. Read SEC document
November 06, 2017 Filed Nov 8, 2017 16:21 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	2,600	$71.67	$186,342.00	Disclosure SEC source: 0001179110-17-013874 · edgar.xml · nonDerivative · entry 4 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,001 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.23 to $72.13 per share. Read SEC document
November 06, 2017 Filed Nov 8, 2017 16:21 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	1,999	$72.91	$145,747.09	Disclosure SEC source: 0001179110-17-013874 · edgar.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,601 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.65 to $73.35 per share. Read SEC document
November 06, 2017 Filed Nov 8, 2017 16:21 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	400	$73.89	$29,556.00	Disclosure SEC source: 0001179110-17-013874 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,600 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.46 to $74.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. Read SEC document
November 06, 2017 Filed Nov 8, 2017 16:21 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	24,514	$1.87	$45,841.18	Disclosure SEC source: 0001179110-17-013874 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 08, 2017 Filed Aug 9, 2017 18:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	10,000	$50.70	$507,000.00	Disclosure SEC source: 0001179110-17-011306 · edgar.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,486 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 19, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.41 to $51.07 per share. Read SEC document
August 07, 2017 Filed Aug 9, 2017 18:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	2,786	$48.29	$134,535.94	Disclosure SEC source: 0001179110-17-011306 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,486 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 19, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.12 to $48.51 per share. Read SEC document
August 07, 2017 Filed Aug 9, 2017 18:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	17,214	$49.21	$847,100.94	Disclosure SEC source: 0001179110-17-011306 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,272 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 19, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.89 to $49.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document
June 28, 2017 Filed Jun 30, 2017 18:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	2,229	$49.10	$109,443.90	Disclosure SEC source: 0001179110-17-009851 · edgar.xml · nonDerivative · entry 3 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,486 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.96 to $49.31 per share. Read SEC document
June 28, 2017 Filed Jun 30, 2017 18:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	10,205	$50.22	$512,495.10	Disclosure SEC source: 0001179110-17-009851 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,715 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.57 to $50.53 per share. Read SEC document
June 28, 2017 Filed Jun 30, 2017 18:18 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	7,566	$51.21	$387,454.86	Disclosure SEC source: 0001179110-17-009851 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,920 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.59 to $51.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document
March 14, 2017 Filed Mar 16, 2017 17:35 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	980	$39.75	$38,955.00	Disclosure SEC source: 0001179110-17-004738 · edgar.xml · nonDerivative · entry 2 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,486 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.71 to $39.78 per share. Read SEC document
March 14, 2017 Filed Mar 16, 2017 17:35 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	19,020	$40.04	$761,560.80	Disclosure SEC source: 0001179110-17-004738 · edgar.xml · nonDerivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,466 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.79 to $40.78 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document
February 16, 2017 Filed Feb 21, 2017 16:27 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	170,000	$0.00 Strike: $36.05	$0.00	Disclosure SEC source: 0001179110-17-002766 · edgar.xml · derivative · entry 1 Albers Jeffrey W. · CIK 0001638474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849,548 Underlying: Common Stock · 170,000 shares Expires 2027-02-16 F1 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.